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ABSTRACT
Background: Transforming growth factor β1 (TGFβ1) is an important factor in immunomodulation. The ex-
pression of TGFβ1 has been shown to be influenced by the C-509T polymorphism in the TGFβ1 gene. We in-
vestigated age-related changes of plasma TGFβ1 levels in a birth-cohort study. In addition, the genotypes of
the C-509T polymorphism were investigated in allergic and non-allergic subjects.
Methods: Sixty-four neonates who met the following criteria were enrolled in this cohort study: 1) full-term va-
ginally delivery; 2) underwent DNA polymorphism analysis; and 3) questionnaire forms were filled out by par-
ents at 0, 6 and 14 months of age. The umbilical cord blood at 0 months and peripheral blood at 6, and 14
months were collected. Plasma TGFβ1 levels were measured at 0, 6 and 14 months of age. Genomic DNA was
extracted from their umbilical cord blood. The genotype of the subjects was examined for the presence of C-
509T.
Results: The plasma TGFβ1 level at 6 months was the highest of the 3 measurements (at 0, 6, and 14 months
of age). The TGFβ1 levels at 14 months in allergic subjects were significantly higher than those in non-allergic
subjects (p = 0.03). All subjects with bronchial asthma (n = 3) had the TT genotype of the C-509T polymor-
phism.
Conclusions: The plasma TGFβ1 levels change with age. In addition, TGFβ1 may play a role in the patho-
genesis of bronchial asthma.
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INTRODUCTION
Transforming growth factorβ1 (TGFβ1) is a 25 kDa
disulfide-linked homodimeric multifunctional cy-
tokine. TGFβ1 may be the most important growth fac-
tor related to immunomodulatory effects because
knockout mice died of massive inflammatory lesions.1
The role of TGFβ1 in allergic diseases have been re-
ported.2-4 The levels of TGFβ1 concentration were
found to be higher in the bronchoalveolar lavage fluid
of patients with asthma compared with subjects with-
out asthma.3 The expression of TGFβ1 was found to
be influenced by polymorphisms in the TGFβ1 gene,
some of which may be associated with bronchial
asthma and other diseases.4,5 In particular, the T al-
lele of the C-509T polymorphism within the TGFβ1
gene was associated with elevated serum TGFβ1 lev-
els and also associated with elevated levels of total
IgE in allergic asthma patients.5,6
In this study, we investigated the age-related
changes of TGFβ1 levels in a birth-cohort study. In
addition, C-509T within the TGFβ1 gene in subjects
with asthma was compared with non-allergic subjects.
METHODS
SUBJECTS
Sixty-four neonates born at Iwasa Maternity Hospital
in Gifu Prefecture between November 2005 and July
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Table 1 Characteristics of subjects
32Female32MaleGender
3137.1 ± 400.5 (range: 2410―4026g)Mean±SDBirth body weight (g)
39w3d ± 1w2d (range: 37w6d―41w1d)Mean±SDGestational week
With alergy 25FatherFamily history of alergy
Without alergy 32
No record 7
With alergy 34Mother 
Without alergy 24
No record 6
48Absent16PresentFamily smoking history with 1 or bothparents stil smoking
Fig. 1 (A) Plasma TGFβ1 levels at 0, 6, and 14 months of age. (B) Changes of plasma TGFβ1 levels in 24 subjects 
whose data were available at al three points.
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2006, and satisfying the following criteria were en-
rolled in this cohort study: 1) full-term vaginally deliv-
ery; 2) underwent DNA polymorphism analysis; and
3) questionnaire forms were filled out by parents at 0,
6 and 14 months of age. Informed consent, including
DNA analysis, was obtained from the parents of the
neonates during their stay in the hospital. This cohort
study was approved by the Ethical Committee of the
Graduate School of Medicine of Gifu University. Um-
bilical cord blood samples were collected from 64
neonates and peripheral blood samples were also col-
lected for analysis from 30 subjects at 6 months and
from 27 subjects at 14 months of age. Subjects who
were given a diagnosis of atopic dermatitis and bron-
chial asthma during the follow-up over a period of 14
months after birth, were classified as having those
diseases. Allergic subjects were defined as those who
were given a diagnosis of atopic dermatitis andor
bronchial asthma and non-allergic subjects were de-
fined as those having neither atopic dermatitis nor
bronchial asthma during the 14-month observation
period. Some data of the recruited population are
summarized in Table 1.
ASSAYS FOR PLASMA IgE LEVELS AND
PLASMA TGFβ1 LEVELS
Plasma samples obtained from heparinized blood
were kept at −30℃. Plasma IgE levels were deter-
mined by chemiluminescent enzyme immunoassay
and plasma TGFβ1 levels were measured with a hu-
man ELISA kit (R & D Systems, Mineapolis, MN,
USA); the detection range was 31.2−2000 pgml.
DETECTION OF C-509T WITHIN THE TGFβ1
GENE
Genomic DNA was extracted from the heparinized
umbilical cord blood using a Sepagene kit (Sanko
Junyaku, Tokyo, Japan). The TGFβ1 gene was ampli-
fied and sequenced using the PCR technique and an
ABI 3100 DNA sequencer (Applied Biosystems, Fos-
ter City, CA, USA). The primers used for amplifica-
tion of the DNA fragments were the forward primer
at position -737− -718 (5’-CAGACTCTAGAGACTGTC
AG-3’) and the reverse primer at position -320− -338
(5’-GTCACCAGAGAAAGAGGAC-3’).
STATISTICAL ANALYSES
The relations between age and plasma in TGFβ1 lev-
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Fig. 2 Plasma TGFβ1 levels of non-alergic and alergic subjects at 0 months (A), 6 months (B) and 14 months 
(C) are shown. The plasma TGFβ1 levels at 14 months of age in alergic subjects were significantly higher than 
those in non-alergic subjects (p＝0.03, C).
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els were determined by using the Mann-Whitney un-
paired U-test. Pearson’s correlation coefficient was
used for statistical analysis of plasma IgE levels and
TGFβ1 levels. The chi-square test was performed for
statistical analysis of allergic symptoms and C-509T
within the TGFβ1 gene. Probability (p) values of less
than 0.05 were considered to indicate statistical sig-
nificance.
RESULTS
ALLERGIC DISORDERS AND SYMPTOMS IN
SUBJECTS
By the age of 14 months, 20 of the 64 subjects were
allergic and 44 were non-allergic as defined in the
Methods. Of the 64 subjects, 19 had atopic dermatitis
and 3 had bronchial asthma, while two subjects suf-
fered from both atopic dermatitis and bronchial
asthma. Peripheral blood samples were collected at 6
months of age in 30 subjects and at 14 months of age
in 27 subjects.
CHANGES IN PLASMA TGFβ1 LEVELS BY AGE
Plasma TGFβ1 levels at 0, 6, and 14 months of age
are shown in Figure 1A. Plasma TGFβ1 levels were
306.2 ± 230.9 pgml (M ± SD) at 0 months (n = 64),
805.3 ± 428.4 pgml at 6 months (n = 30), and 273.6 ±
175.8 pgml at 14 months (n = 27). Plasma TGFβ1
levels at 6 months of age were significantly (p <
0.0001 for each) higher than those in both 0 months
and 14 months.
TGFβ1 levels were measured at all 3 points in all 24
subjects (data shown in Fig. 1B). The plasma TGFβ1
levels at 6 months of age were significantly (p <
0.0001 for each) higher than at both 0 and 14 months.
This pattern was observed in 22 of the 24 subjects
whose plasma TGFβ1 levels were measured at all 3
points.
RELATIONSHIP BETWEEN PLASMA TGFβ1
LEVELS AND ALLERGIC DISEASES OR
PLASMA IgE LEVELS
Figure 2A, B, C show plasma TGFβ1 levels at 0, 6,
and 14 months of age in non-allergic and allergic sub-
jects. The plasma TGFβ1 levels at 14 months of age
in allergic subjects were significantly higher than
those in the non-allergic subjects (p = 0.03, Fig. 2C).
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Fig. 3 Relationship between C-509T SNP of TGFβ1 gene and plasma TGFβ1 levels at 0 months (A), 6 months 
(B) and 14 months (C) is shown.
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We also investigated the relationship between
plasma IgE levels and TGFβ1 levels at 0, 6 and 14
months of age and found no significant relations (0
months; p = 0.368, 6 months; p = 0.778, 14 months; p =
0.818, data not shown).
PLASMA TGFβ1 LEVELS AND TGFβ1 C-509T
POLYMORPHISM
Among the 64 subjects, 22, 25 and 17 were classified
as genotype CC, CT, and TT, respectively. As shown
in Figure 3, these genotypes were not significantly re-
lated with plasma TGFβ1 levels at either 0, 6, or 14
months of age.
TGFβ1 C-509T POLYMORPHISM AND ALLERGIC
DISEASES
The genotypes of TGFβ1 C-509T polymorphism were
not associated with the prevalence of atopic dermati-
tis at 6 months of age (Table 2) and 14 months of age
(Table 3). However, the TT genotype was present in
the TGFβ1 gene (C-509T) in all 3 patients with
asthma at 14 months of age (Table 4). Furthermore,
the TGFβ1 levels (M ± SD; 651.42 ± 544.79 pgml) in
patients with asthma having the TT genotype in the
TGFβ1 gene (C-509T) were higher than the TGFβ1
levels (M ± SD; 243.75 ± 89.19 pgml) in subjects
without asthma (CC, CT or TT genotypes) at 14
months.
DISCUSSION
TGFβ1 is a multifunctional cytokine that has immuno-
modulatory effects produced by airway epithelial
cells, eosinophils, helper T type 2 lymphocytes,
macrophages, and fibroblasts. An important finding
in this study is the changing pattern of plasma TGFβ1
levels over time at 0, 6, and 14 months of age. Plasma
TGFβ1 levels at 6 months of age were the highest
among these 3 measured age points. This pattern was
observed in 22 of the 24 subjects whose plasma
TGFβ1 levels were available at all 3 points. Statisti-
cally, the plasma TGFβ1 level at 6 months of age was
significantly higher than that at 0 months and at 14
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Table 2 Genotype frequency of C-509T TGF-β1 promoter 
SNP in subjects with/without atopic dermatitis at 6 months
TotalTTCTCC
47 (74%)121718Without atopic dermatitis
17 (26%) 5 8 4With atopic dermatitis
(p＝0.551)
Table 3 Genotype frequency of C-509T TGF-β1 promoter 
SNP in subjects with/without atopic dermatitis at 14 months
TotalTTCTCC
49 (77%)121918Without atopic dermatitis
15 (23%) 5 6 4With atopic dermatitis
(p＝0.865)
Table 4 Genotype frequency of C-509T TGF-β1 promoter 
SNP in subjects with/without bronchial asthma at 14 months
TotalTTCTCC
61 (96%)142522Without bronchial asthma
 3 ( 4%) 3 0 0With bronchial asthma
(p＝0.016)
months of age (p < 0.0001 for each). We believe this
is the first time this unique change in the plasma
TGFβ1 level has been reported.
A previous study showed that the range of plasma
TGFβ1 levels was 2000−4000 pgml in adult popula-
tion.5 In our study, the range of plasma TGFβ1 levels
at 0, 6, and 14 months of age was 0−2500 pgml, and
was lower than that of adult populations. At present,
we do not know what causes the plasma TGFβ1 level
changes, but one possible explanation could be that
TGFβ1 is necessary for dramatic changes in immu-
nological response or maturation at around 6 months
of age. In other studies, the CD4 or CD8 cells produc-
ing cytokines, including TGFβ1, increased with
age.7,8 An increase in the number of TGFβ1- produc-
ing cells may partially explain why TGFβ1 production
at 6 months was higher than that at 0 months. We are
planning to observe further changes in plasma
TGFβ1 levels from 14 months of age to 5 years of age
or older.
We could not find any association of IgE with
TGFβ1 in this study. TGFβ1 is produced by various
cells including airway epithelial cells, eosinophils,
lymphocytes, macropharges, and fibroblasts.9,10 Vari-
ous cell factors should be considered to evaluate the
level of plasma TGFβ1.
It has been hypothesized that the T allele of the C-
509T SNP enhances the Yin Yang 1 (YY1) transcrip-
tion factor consensus binding site (-CCATCTCTG-)
on the TGFβ1 promoter and is responsible for in-
creased TGFβ1 transcription.11 In the present study
there were no significant differences in plasma
TGFβ1 levels at 0, 6, and 14 months of age regarding
genotypes of TGFβ1 C-509T. Pulleyn has shown that
the T allele of the C-509T SNP is associated with the
diagnosis of asthma and asthma severity.12 In this
study, only 3 subjects were given a diagnosis of bron-
chial asthma by the age of 14 months. Interestingly,
the TT genotype was present in these 3 subjects (Ta-
ble 4, p = 0.016). Although the prevalence of bron-
chial asthma at 14 months of age is low we need to
obtain data at 5 years of age for an accurate evalu-
ation of the role of the TGFβ1 polymorphism in bron-
chial asthma. We are planning to increase the num-
ber of subjects to participate in future studies and to
conduct a follow up for a longer time span.
In conclusion, this birth-cohort study suggests that
plasma TGFβ1 levels are influenced by age and that
the C-509T SNP of the TGFβ1 gene is an important
susceptibility locus for asthma in infants at 14 months
of age, despite the fact that the number of subjects
who participated in this study was limited.
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